Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
Clinical trial NCT00610311 · TERMINATED
Trial details
- NCT number
- NCT00610311
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-01-01
- Primary completion
- 2011-02-01
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.